Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01212861 · ClinicalTrials.gov registry record · NA
Surgical Treatment of Refractory Open Angle Glaucoma
A NA study of Open Angle Glaucoma, sponsored by iScience Interventional Corporation.
- Completed
- Registry status
- NA
- Development phase
- 4
- Enrollment target
- 1
- Study location
NCT01212861 is a NA study of Open Angle Glaucoma that has completed, run by iScience Interventional Corporation. The registered enrollment target is 4 participants, below the 334-participant average among 28 other Open Angle Glaucoma trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01212861, a NA study of Open Angle Glaucoma, has completed, sponsored by iScience Interventional Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 4 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this study is to evaluate the safety, efficacy, and performance of the Suprachoroidal Dissection Instrument in creating a fistula between Schlemm's canal and the suprachoroidal space in refractory, open angle glaucoma subjects.
Conditions Studied
Interventions
- DEVICE Suprachoroidal Dissection Instrument (SDI)
Study Locations (1)
Texas
- Glaucoma Associates of Texas - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2010-08 |
| Est. Completion | 2012-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01212861
The ClinicalTrials.gov registry entry for NCT01212861 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 334-participant average among 28 other Open Angle Glaucoma trials with a reported enrollment target (99% lower). The listed sponsor is iScience Interventional Corporation, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Open Angle Glaucoma appearing as the primary indexed condition, and to 1 intervention - of which Suprachoroidal Dissection Instrument (SDI) is the first listed.
NCT01212861 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT01212861 about?
NCT01212861 is a clinical study titled "Surgical Treatment of Refractory Open Angle Glaucoma". The primary objective of this study is to evaluate the safety, efficacy, and performance of the Suprachoroidal Dissection Instrument in creating a fistula between Schlemm's canal and the suprachoroidal space in refractory, open angle glaucoma subjects.
What is the current status of trial NCT01212861?
This trial is currently completed. It is a NA study. The enrollment target is 4 participants. The study started on 2010-08. Estimated completion is 2012-05.
What conditions does trial NCT01212861 study?
This clinical trial studies the following conditions: Open Angle Glaucoma.
What interventions are being tested in trial NCT01212861?
The interventions under investigation include: Suprachoroidal Dissection Instrument (SDI) (DEVICE).
Who is sponsoring clinical trial NCT01212861?
This trial is sponsored by iScience Interventional Corporation, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01212861 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Open Angle Glaucoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Effectiveness of Minimally Invasive Micro Sclerostomy (MIMS®) to Reduce Intraocular Pressure in Open-Angle Glaucoma Which is Not Controlled Despite Polypharmacy
RECRUITING · NA
-
STREAMLINE®SURGICAL SYSTEM Compared to iStent Inject W® in Patients With Open-Angle Glaucoma
ACTIVE NOT RECRUITING · NA
-
24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients
RECRUITING · Phase 4
-
Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost
RECRUITING · Phase 4
-
Standalone iStent Infinite and iDose TR for Management of Moderate to Severe Open Angle Glaucoma
RECRUITING · Phase 4
-
A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.